Guardant Health, Inc. (GH)

NASDAQ • Currency in USD

$373.00

-$6.24

-1.64%

Last Update: 18 Jul 2026, 12:53

$46.76bn

Market Cap

-110.03

P/E Ratio (TTM)

—

Forward Dividend Yield

$242.66-$519.52

52 Week Range

GH Stock Price Chart

Explore Guardant Health, Inc. interactive price chart. Choose custom timeframes to analyze GH price movements and trends.

GH Company Profile

Discover essential business fundamentals and corporate details for Guardant Health, Inc. (GH) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

IPO Date

4 Oct 2018

Employees

2.00k

Website

https://guardanthealth.com

CEO

Helmy Eltoukhy

Description

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

GH Financial Timeline

Browse a chronological timeline of Guardant Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 30 Jul 2026

EPS estimate is -$0.41, while revenue estimate is $314.23m.

Earnings released on 7 May 2026

EPS came in at -$0.85 falling short of the estimated -$0.81 by -5.46%, while revenue for the quarter reached $301.67m , beating expectations by +8.07%.

Earnings released on 19 Feb 2026

EPS came in at -$0.90 falling short of the estimated -$0.77 by -17.38%, while revenue for the quarter reached $281.27m , beating expectations by +3.25%.

Earnings released on 29 Oct 2025

EPS came in at -$0.39 surpassing the estimated -$0.48 by +18.75%, while revenue for the quarter reached $265.20m , missing expectations by -0.90%.

Earnings released on 30 Jul 2025

EPS came in at -$0.44 surpassing the estimated -$0.52 by +15.38%, while revenue for the quarter reached $232.09m , missing expectations by -1.54%.

Earnings released on 30 Apr 2025

EPS came in at -$0.49 surpassing the estimated -$0.61 by +19.67%, while revenue for the quarter reached $203.47m , missing expectations by -3.77%.

Earnings released on 20 Feb 2025

EPS came in at -$0.62 surpassing the estimated -$0.75 by +17.33%, while revenue for the quarter reached $201.81m , beating expectations by +4.84%.

Earnings released on 6 Nov 2024

EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%, while revenue for the quarter reached $191.48m , beating expectations by +1.30%.

Earnings released on 7 Aug 2024

EPS came in at -$0.48 surpassing the estimated -$0.57 by +15.79%, while revenue for the quarter reached $177.24m , beating expectations by +8.93%.

Earnings released on 9 May 2024

EPS came in at -$0.46 surpassing the estimated -$0.72 by +36.11%, while revenue for the quarter reached $168.49m , beating expectations by +11.82%.

Earnings released on 22 Feb 2024

EPS came in at -$1.58 falling short of the estimated -$0.93 by -69.89%, while revenue for the quarter reached $155.05m , beating expectations by +3.67%.

Earnings released on 6 Nov 2023

EPS came in at -$0.73 surpassing the estimated -$0.93 by +21.51%, while revenue for the quarter reached $143.03m , beating expectations by +4.12%.

Earnings released on 3 Aug 2023

EPS came in at -$0.67 surpassing the estimated -$1.25 by +46.40%, while revenue for the quarter reached $137.15m , beating expectations by +5.98%.

Earnings released on 9 May 2023

EPS came in at -$1.30 falling short of the estimated -$1.26 by -3.17%, while revenue for the quarter reached $128.71m , beating expectations by +9.17%.

Earnings released on 23 Feb 2023

EPS came in at -$1.36 surpassing the estimated -$1.40 by +2.86%, while revenue for the quarter reached $126.89m , beating expectations by +2.48%.

Earnings released on 3 Nov 2022

EPS came in at -$1.58 falling short of the estimated -$1.27 by -24.41%, while revenue for the quarter reached $117.40m , missing expectations by -0.29%.

Earnings released on 4 Aug 2022

EPS came in at -$2.25 falling short of the estimated -$1.25 by -80.00%, while revenue for the quarter reached $109.14m , beating expectations by +3.87%.

Earnings released on 5 May 2022

EPS came in at -$1.21 surpassing the estimated -$1.23 by +1.63%, while revenue for the quarter reached $96.10m , beating expectations by +0.35%.

Earnings released on 23 Feb 2022

EPS came in at -$0.89 surpassing the estimated -$1.13 by +21.24%, while revenue for the quarter reached $108.11m , beating expectations by +9.59%.

Earnings released on 4 Nov 2021

EPS came in at -$1.06 falling short of the estimated -$0.90 by -17.78%, while revenue for the quarter reached $94.78m , beating expectations by +0.87%.

Earnings released on 5 Aug 2021

EPS came in at -$0.96 falling short of the estimated -$0.87 by -10.34%, while revenue for the quarter reached $92.10m , beating expectations by +8.85%.